Ann: Proposed Consolidation of Capital, page-454

sane analysis will get good replies, thank you, also Iovance Biotherapeutics had used IL-2 in Tumor-infiltrating lymphocyte therapy which received accelerated FDA approval (February 16, 2024) as the first cell therapy for an unresectable or metastatic solid tumor (melanoma),

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanomaafter that havent seen much drugs using Il-2 as overall therapeutic window is narrow for IL-2 (so its perceived or detered Precision to use it), but look at what Imugene has achieved

Clinical proof-of-concept

Imugene observed 3 complete responses in 4 evaluable patients in the IL-2 cohort—an objective response rate of 75 %—versus 1 in 6 in the non-IL-2 cohort. CEO Leslie Chong highlighted that to maximise response rates and durability…we added a very low dose of IL-2,” underscoring that enhanced persistence likely drives these deeper remissions

Imugene is using low-dose IL-2 with Azer-cel to achieve the “sweet spot” where you get the immunologic benefits of cytokine-driven CAR-T expansion without the prohibitive toxicities of high-dose IL-2—translating directly into higher response rates and potentially more durable remissions

If Imugene continously gets sucess with IL-2 it will itself open up another paradigm in combination therapy